Send to

Choose Destination
Breast. 2013 Aug;22 Suppl 2:S106-9. doi: 10.1016/j.breast.2013.07.020.

Personalizing extent of breast cancer surgery according to molecular subtypes.

Author information

Memorial Sloan-Kettering Cancer Center, 300 East 66th Street, New York, NY 10065, USA. Electronic address:


The molecular subtype of breast cancer is the major determinant of the type of systemic therapy, but less attention has been paid to the impact of subtype on local therapy outcomes. Presenting features of breast cancer vary with hormone receptor status, with triple negative cancers being significantly less likely than hormone receptor positive cancers to have nodal metastases, and HER2 overexpressing cancers being more likely to be multifocal or multicentric and to have an extensive intraductal component. The risk of local recurrence varies with subtype as well, with triple negative cancers having the highest risk of local recurrence after both breast-conserving therapy and mastectomy, indicating that bigger surgery does not overcome bad biology.


Local recurrence; Local therapy; Molecular subtype

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center